In this retrospective single-center analysis of 128 adults with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation, pretransplant therapy did not translate into better post-transplant outcomes.
Although IPSS-M improved before transplantation in a subset of patients, molecular or composite-risk “downstaging” was modest and showed no clear survival advantage.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
